Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China
JPM Session Predicts Mixed Outlook
Executive Summary
Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.
You may also be interested in...
Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.
China Alzheimer's Approval Raises Hope But Also Questions
While the approval in China of a novel algae-derived drug for Alzheimer's appears to be a breakthrough, it has also left some wondering about long-term efficacy and the reasons for the apparent rush to grant the clearance ahead of a major pending filing for the disease in the US.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.